A fused ring compound and a pharmaceutical preparation containing it

EA202691290A1Pending Publication Date: 2026-07-14KAKEN PHARMA CO LTD

View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office: EA · EA
Patent Type: Applications
Current Assignee / Owner: KAKEN PHARMA CO LTD
Filing Date: 2023-09-29
Publication Date: 2026-07-14

Application Information

Patent Timeline

29 Sep 2023

Application

14 Jul 2026

Publication

EA202691290A1

IPC: C07D401/14; A61K31/4184; A61K31/4196; A61K31/433; A61K31/437; A61K31/4439; A61K31/501; A61K31/506; A61K31/5377; A61P1/04; A61P11/00; A61P11/02; A61P11/06; A61P17/00; A61P17/04; A61P29/00; A61P37/08; C07D235/14; C07D403/10; C07D403/14; C07D413/10; C07D417/14; C07D471/04

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗

Get free access to AI patent search and analysis

Check patentability, review prior art and ask IP Agent with full patent context.

Smart Images

Figure CLAIM-14072026-IMGA0001

Patent Text Reader

Abstract

The present invention provides a novel compound that exhibits STAT6 inhibitory activity and is effective for the treatment of inflammatory diseases such as atopic dermatitis and allergic diseases. A pharmaceutically acceptable salt of the compound, represented by general formula (I), exhibits STAT6 inhibitory activity.

Need to check novelty before this filing date? Find Prior Art